Ministry of Food and Drug Safety advises targeting rhinitis symptoms

Allergic rhinitis symptoms require targeted pharmacological interventions according to specific symptom presentations, the Ministry of Food and Drug Safety stated on the 5th. Data shows that allergic rhinitis accounts for approximately two-thirds of all rhinitis cases, triggered by airborne allergens such as pollen, mold, house dust mites, and animal hair.

Key Clinical Takeaways:

• Allergic rhinitis represents about two-thirds of all rhinitis cases, driven by common environmental allergens like pollen, dust mites, and animal dander.
• Second- and third-generation antihistamines are clinically preferred over older first-generation drugs because they provide longer-lasting relief with fewer side effects like drowsiness.
• Decongestants effectively target nasal congestion through vasoconstriction, but continuous use beyond one week risks aggravating symptom severity.

Clinicians Classify Rhinitis by Temporal Patterns and Severity

Clinical evaluation of rhinitis relies on distinct temporal patterns and severity markers. When nasal symptoms present for less than four days per week or persist for under four weeks, clinicians classify the condition as intermittent. Conversely, symptoms occurring four or more days weekly for four consecutive weeks or longer fall under the persistent category. Regulatory guidance indicates that physicians also grade severity based on how significantly the condition disrupts daily functioning and sleep quality, ranging from mild to moderate and severe.

Higher Generation Antihistamines Reduce Sedation and Other Side Effects

Over-the-counter management of allergic rhinitis primarily involves antihistamines and decongestants. Antihistamines manage generalized allergic manifestations including hives, pruritus, and acute presentation of sneezing and profuse clear nasal discharge. These medications are categorized into three developmental generations. Second- and third-generation agents—including cetirizine, loratadine, and fexofenadine—are clinically prioritized over first-generation options. Higher generations offer extended duration of action alongside reduced rates of sedation, xerostomia, tachycardia, and constipation. Despite these favorable profiles, individual variability in sedative response persists, and concurrent administration with other central nervous system depressants demands caution.

Decongestants Alleviate Nasal Obstruction Through Oral and Topical Forms

While antihistamines control sneezing and rhinorrhea, they do not alleviate nasal obstruction. When blocked nasal passages dominate the clinical picture, patients require decongestants to constrict swollen nasal blood vessels. These formulations are available as oral medications and topical nasal sprays. Single-ingredient oral decongestants containing pseudoephedrine are classified as prescription-only drugs, whereas combination products blending decongestants with antihistamines like triprolidine or mequitazine remain available over-the-counter. Nasal spray formulations should be administered one to three times daily, maintaining intervals of approximately eight hours between doses. Patients must apply a single spray per nostril directed toward the outer nasal wall rather than the nasal septum. Continuous use exceeding one week can paradoxically worsen nasal blockage via rebound congestion. Because vasoconstrictors elevate vascular tone, patients diagnosed with hypertension or glaucoma must consult a physician or pharmacist prior to use.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.